Glenmark launches much awaited COVID-19 drug after DCGI nod -MRP at Rs 103 per tablet

Glenmark launches much awaited COVID-19 drug after DCGI nod
-MRP at Rs 103 per tablet

Drug Firm Glenmark Pharmaceuticals informed on Saturday that it had launched the antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19. It is priced moderately at Rs 103 per tablet. The drug will be available as a 200 mg tablet at a Maximum Retail Price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.
FabiFlu is the first oral Favipiravir-approved medication in India for the treatment of COVID-19. It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, said a release from the Glenmark Pharma.

Report of amit singh negi for idea for news from dehradun.